Pulse Biosciences, Inc. Share Price

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 09:42:50 29/04/2024 pm IST 5-day change 1st Jan Change
7.32 USD +1.81% Intraday chart for Pulse Biosciences, Inc. +7.30% -39.95%
Sales 2021 1.42 118.27 Sales 2022 0.7 58.38 Capitalization 103M 8.6B
Net income 2021 -63M -5.25B Net income 2022 -58M -4.84B EV / Sales 2021 29,72,32,229 x
Net cash position 2021 17.36M 1.45B Net Debt 2022 14.82M 1.24B EV / Sales 2022 16,84,85,877 x
P/E ratio 2021
-6.51 x
P/E ratio 2022
-1.61 x
Employees 61
Yield 2021 *
-
Yield 2022
-
Free-Float 29.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.83%
1 week+7.30%
Current month-15.61%
1 month-8.01%
3 months-20.80%
6 months+66.67%
Current year-39.95%
More quotes
1 week
6.60
Extreme 6.595
7.69
1 month
6.60
Extreme 6.595
8.34
Current year
6.60
Extreme 6.595
12.22
1 year
3.78
Extreme 3.78
13.62
3 years
1.18
Extreme 1.18
29.16
5 years
1.18
Extreme 1.18
45.82
10 years
1.18
Extreme 1.18
45.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 14/22/14
Chief Tech/Sci/R&D Officer - 03/23/03
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 79 02/17/02
Director/Board Member 46 02/17/02
Chief Tech/Sci/R&D Officer 59 15/15/15
More insiders
Date Price Change Volume
29/24/29 7.35 +2.23% 83 520
26/24/26 7.19 +7.47% 71,325
25/24/25 6.69 -2.48% 117,307
24/24/24 6.86 0.00% 129,156
23/24/23 6.86 +0.15% 124,448

Delayed Quote Nasdaq, April 29, 2024 at 09:27 pm IST

More quotes
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Calendar
Related indices
More about the company